CORRECTION article

Front. Immunol., 08 April 2024

Sec. Cytokines and Soluble Mediators in Immunity

Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1386412

Corrigendum: Mesenchymal stromal cell derived extracellular vesicles as a therapeutic tool: immune regulation, MSC priming, and applications to SLE

  • 1. EVerZom, Paris, France

  • 2. Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche (UMR) 8601, Université Paris Cité, Paris, France

  • 3. Chemistry and Biology, Modeling and Immunology for Therapy (CBMIT), Université Paris Cité, Paris, France

  • 4. Matière et Systèmes Complexes (MSC) UMR CNRS 7057, Université Paris Cité, Paris, France

In the published article, there was an error in the Funding statement. A funding information was not included in the article. The correct Funding statement appears below.

Statements

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. CW is a student from the FIRE PhD program funded by the Bettencourt Schueller foundation and the EURIP graduate program (ANR-17-EURE-0012). IS is a student from the MTCI PhD program, and this work was supported by the Fondation pour la Recherche Médicale, grant number ECO202306017404.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

extracellular vesicles, secretome, immune regulation, mesenchymal stromal cell, priming, systemic lupus erythematosus

Citation

Wong C, Stoilova I, Gazeau F, Herbeuval J-P and Fourniols T (2024) Corrigendum: Mesenchymal stromal cell derived extracellular vesicles as a therapeutic tool: immune regulation, MSC priming, and applications to SLE. Front. Immunol. 15:1386412. doi: 10.3389/fimmu.2024.1386412

Received

27 March 2024

Accepted

27 March 2024

Published

08 April 2024

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

15 - 2024

Updates

Copyright

*Correspondence: Jean-Philippe Herbeuval, ; Thibaut Fourniols,

†These authors have contributed equally to this work and share last authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics